AUTHOR=Lehloenya Rannakoe J. 

TITLE=Disease severity and status in Stevens–Johnson syndrome and toxic epidermal necrolysis: Key knowledge gaps and research needs

JOURNAL=Frontiers in Medicine

VOLUME=Volume 9 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.901401

DOI=10.3389/fmed.2022.901401

ISSN=2296-858X

ABSTRACT=Stevens Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are on a spectrum of  cutaneous drug reactions characterised by pan-epidermal necrosis with SJS affecting  <10 % of body surface area (BSA), TEN > 30% and SJS/TEN overlap between 10 and 30%. Severity-of-illness score for toxic epidermal necrolysis (SCORTEN) is a validated tool to predict mortality rates based on  age, heart rate, BSA), malignancy and serum urea, bicarbonate and glucose. Despite improved understanding, SJS/TEN mortality remains constant and therapeutic interventions not universally accepted for a number of reasons. These include rarity of SJS/TEN; inconsistent definition of cases, disease severity, and endpoints in studies; low efficacy of interventions; and variations in treatment protocols. Mortality aside, none of the other endpoints used to evaluate interventions, including duration of hospitalization,  are sufficiently standardized to be reproducible across cases and treatment centres. 

Some of the gaps in SJS/TEN research can be narrowed through international collaboration to harmonize research endpoints. A case is made for an urgent international collaborative effort to develop consensus on definitions of endpoints such as disease status, progression, cessation and complete re-epithelialization in interventional studies. The deficiencies of using  BSA as the sole determinant of SJS/TEN severity, excluding internal organ involvement and extension of skin necrosis beyond the epidermis are discussed and the role these factors play on time to healing and mortality beyond the acute stage is highlighted. The potential role of artificial intelligence, biomarkers, and PET/CT scan with radiolabelled glucose as markers of disease status, activity and therapeutic response are discussed.